LncRNA expression in prostate cancer: From <i>in silico</i> analysis to urinary EV-based liquid biopsy for prognosis.

ABSTRACT: Prostate cancer (PCa) is the most frequently diagnosed malignancy among men and remains a leading cause of cancer-related death. Despite the widespread use of diagnostic tools such as PSA testing and Gleason scoring, these methods often fall short in accurately predicting tumor progression, highlighting the urgent need for reliable, non-invasive biomarkers to improve prognosis. In this study, we explored the potential of long non-coding RNAs (lncRNAs) as novel prognostic biomarkers for PCa. An initial in silico analysis of public datasets identified six lncRNAs differentially expressed in PCa tissues compared to healthy and adjacent non-tumor tissues. Of these, three were validated in a cohort of prostate cancer and benign prostatic hyperplasia (BPH) tissue samples. Notably, four ln

SUBMITTER: De Summa S 

PROVIDER: S-EPMC12639622 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature